SPINAL MUSCULAR ATROPHY MARKET ANALYSIS

Spinal Muscular Atrophy Market, by Type (Type I, Type II, Type III, and Type IV), by Treatment (Gene Therapy and Disease-modifying drugs), by Age Group (Infant and Adult), by Route of Administration (Oral and Injectables), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2024 - 2031

Published In : Mar 2024
Code : CMI1920
Pages :156
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Restraints & Challenges:

High cost of the treatment

Global Spinal Muscular Atrophy Market: Restraint

The major factor that hinder growth of the global spinal muscular atrophy market include high cost of the treatment. For instance, according to an article published by MJH Life Sciences, largest privately held medical media company in the U.S., in March 2021, the mean per-patient annual direct medical cost was estimated to be between US$ 3,320 (spinal muscular atrophy type 3) in Italy and US$ 324,210 (type 1) in the U.S., with the variability high for other measures as well.

Growth Drivers: